• Esma Eren, Ayşegül Ulu-Kılıç, Serdal Korkmaz, Merve Yıldız, Recep Civan Yüksel, Ayşin Kılınç-Toker, Emine Arman-Fırat, Zehra Bestepe-Dursun, and Ilhami Çelik.
• MD. Physician, Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Kayseri City Education and Research Hospital, Kayseri, Turkey.
• Sao Paulo Med J. 2022 Jan 1; 140 (1): 121612-16.

BackgroundCoronavirus disease 2019 (COVID-19) is an ongoing global health threat. However, currently, no standard therapy has been approved for the disease.ObjectivesTo evaluate the clinical effectiveness of convalescent plasma (CP) in patients with acute respiratory distress syndrome (ARDS) due to COVID-19.Design And SettingRetrospective study conducted at Kayseri City Education and Research Hospital, Kayseri, Turkey.MethodsThe case group consisted of adult patients (> 18 years) with ARDS due to COVID-19 who received CP in combination with antiviral and supportive treatment. These patients were compared with others who only received antiviral and supportive treatment.ResultsDuring the study period, a total of 30 patients with ARDS due to COVID-19 were included. Eleven patients (36%) received CP in combination with antiviral and supportive treatment, whereas nineteen patients (64%) in the control group only received antiviral and supportive treatment. On admission, the median age, demographic and clinical data and initial laboratory test results were similar between the groups (P > 0.05). On the 14th day of treatment, the laboratory values remained similar between the groups (P > 0.05). The mortality rates were not significantly different between the groups.ConclusionCP treatment did not affect mortality or lead to clinical improvement for COVID-19 patients with ARDS.

12 keywords...

hide…